Product Description
Atazanavir is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children who are at least 3 months of age and weigh at least 22 lb (10 kg). Atazanavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although atazanavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a603019.html)
Mechanisms of Action: HIV Protease Inhibitor,Protease Inhibitor,UGT1A1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: HIV Infections
Known Adverse Events: Depressive Disorder | Abdominal Pain | Dizziness | Headache | Pain Unspecified | Myalgia | Diarrhea
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Burkina Faso, Cameroon, Ivory Coast, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: HIV Infections
Phase 1: Healthy Volunteers|Malnutrition
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MODERATO | P3 |
Active, not recruiting |
HIV Infections |
2025-02-05 |
|
AI424-578 | P1 |
Completed |
Malnutrition |
2022-07-05 |
28% |
2006-7041-83/hah | P1 |
Not yet recruiting |
Healthy Volunteers |
None |